For laboratory research use only. Not for human consumption.
Free cold-chain shipping over $200 CAD · Ships from Kelowna, BC

Lumera Labs Journal · Compendium

Retatrutide vs Tirzepatide: receptor-engagement comparison for research

Published 2024-02-19 · Lumera Labs Editorial · Kelowna, BC

Short answer. Tirzepatide engages two incretin receptors (GLP-1, GIP); Retatrutide adds the glucagon receptor for triple agonism, which broadens the downstream signaling pattern but complicates the pharmacology in cell-based screens.

Receptor engagement at a glance

CompoundGLP-1RGIPRGCGRLength
Semaglutide30 res
Tirzepatide39 res
Retatrutide39 res

Why the third receptor matters in research

Glucagon receptor activation is hepatic-leaning: GCGR drives gluconeogenesis and lipolysis under physiological conditions, but in receptor-binding assays it changes the affinity panel a researcher needs to interpret. A clean Tirzepatide screen runs against two HEK293-receptor lines; Retatrutide work needs three.

Half-life and lipidation

Both peptides carry γGlu-C20 fatty-diacid modifications for albumin binding, producing comparable plasma half-lives (~five to seven days in published human PK). For in-vitro work this is irrelevant on the assay timescale, but it complicates translation interpretation in animal models.

What to verify on each COA

  • Tirzepatide: ≥ 99% RP-HPLC, ESI-MS within 0.5 Da of 4813.45.
  • Retatrutide: ≥ 99% RP-HPLC, ESI-MS within 0.5 Da of 4731.42.
  • Both should show net peptide ≥ 80% by AAA and endotoxin < 0.5 EU/mg.

Stocking both

Researchers running a class-comparison study should source both from the same supplier in the same release window — different vendors layer in different counter-ion content and different storage history, making cross-class comparisons noisier than they need to be. Lumera ships Retatrutide from $45 CAD and Tirzepatide from $40 CAD with paired Janoshik COAs.

Lumera Labs ships HPLC-verified Retatrutide cold-chain across Canada from $45 CAD. View Retatrutide on the catalog →


Frequently asked questions

Which is more potent in vitro: Retatrutide or Tirzepatide?

Both bind their target receptors at low-nanomolar affinity in published assays. Direct comparison depends on the cell line and readout; Retatrutide's tri-receptor profile makes single-readout comparisons inadequate.

Can I run them in the same buffer?

Both reconstitute cleanly at neutral pH in bacteriostatic water. Use the same buffer composition across the comparison to avoid solvent-effect artifacts.

How do molecular weights compare?

Tirzepatide ~4813 Da, Retatrutide ~4731 Da. Both are 39-residue chains with C20 fatty-diacid modification.

Do they need separate cold-chain shipments?

No — both are stable lyophilized at −20 °C. Lumera ships them together in the same insulated package when ordered jointly.

Is there a tri-agonist with a different lipidation?

Several non-clinical tri-agonist scaffolds exist in the literature, but Retatrutide is the most-characterized clinically-translated example as of 2024.


Disclaimer: All Lumera Labs products are supplied for laboratory research use only. They are not approved by Health Canada for human consumption, therapy, or diagnosis. See our research-use declaration for full terms.

Browse the catalog →